Caplin Point Laboratories (524742) investor relations material

Executive summary

• H1 FY26 revenue reached ₹1,098 Crores, up 11.9% YoY, with PAT at ₹311 Crores, up 21.6% YoY, and US market revenue growing 27% YoY to ₹221 Crores.

• Recognized as a top wealth creator in India, with a strong presence in Latin America, Francophone Africa, and expansion into regulated markets like the US, Canada, and Australia.

• Maintains a strong cash position with liquid assets at ₹2,358 Crores and net worth crossing ₹3,000 Crores.

• Focus on asset-light model, operational productivity, R&D-driven new market entry, and expansion in Latin America, US, Mexico, and Guatemala.

• Board approved unaudited results and appointed new directors, including an independent director.

Financial highlights

• Q2 FY26 revenue from operations rose 12% YoY to ₹564 Crores; H1 FY26 revenue up 11.9% to ₹1,098 Crores.

• H1 FY26 EBITDA was ₹420.4 Crores, up 18.1% YoY, with EBITDA margin at 38.3%; PAT margin at 28.3%.

• Q2 FY26 PAT grew 22.5% YoY to ₹160 Crores; H1 FY26 PAT up 21.6% to ₹311 Crores.

• Cash and cash equivalents at ₹1,334 Crores as of September 30, 2025.

• Free cash flow in H1 FY26 was ₹160 Crores after capex of ₹94 Crores.

Outlook and guidance

• Targeting 20-25% growth over the next two years, with expectations of 40% operating margins after two years if market conditions remain favorable.

• Expansion into regulated markets (US, Canada, Mexico, Chile, Colombia, Brazil) and continued focus on cashflows, profitability, and compliance.

• Capex budget of over ₹1,000 Crores for capacity expansion and backward integration, fully funded by internal accruals.